Flucytosine


Generic Medicine Info
Administration
May be taken with or without food. Nausea & vomiting may be minimised if the dose is spaced over a 15-min period.
Contraindications
Hypersensitivity to flucytosine. Co-administration w/ antiviral nucleoside drugs and their analogues. Lactation.
Special Precautions
Patient w/ blood dyscrasias or bone marrow depression, dihydropyrimidine dehydrogenase (DPD) deficiency, or those receiving radiation therapy. Renal and hepatic impairment. Monitoring Parameters Monitor renal, hepatic, and haematologic functions prior to and during treatment (at least wkly in patients w/ renal impairment or blood dyscrasia).
Adverse Reactions
Nervous: Ataxia, confusion, hallucinations, psychosis, headache, paraesthesia, peripheral neuropathy, parkinsonism, seizures, vertigo, sedation. CV: Cardiac arrest, myocardial toxicity, ventricular dysfunction, chest pain. GI: Abdominal pain, dry mouth, bloating, diarrhoea, duodenal ulcer, GI haemorrhage, nausea, vomiting, ulcerative colitis, anorexia. Resp: Dyspnoea, resp arrest. Hepatic: Hepatic dysfunction, jaundice, elevated serum alkaline phosphatase, AST, ALT, and bilirubin. Genitourinary: Increased BUN and serum creatinine, azotaemia, crystalluria, renal failure. Endocrine: Hypoglycaemia. Haematologic: Leucopenia, anaemia, pancytopenia, thrombocytopenia, eosinophilia, agranulocytosis. Otic: Hearing loss. Dermatologic: Pruritus, rash, urticaria, photosensitivity, toxic epidermal necrolysis. Others: Fatigue, pyrexia, hypokalaemia, weakness.
Potentially Fatal: Bone marrow toxicity, acute hepatic injury.
Drug Interactions
May result in synergistic effect when combined w/ amphotericin B or fluconazole. May increase phenytoin plasma levels. Cytarabine antagonises the antifungal activity of flucytosine by competitive inhibition.
CIMS Class
Antifungals
ATC Classification
D01AE21 - flucytosine ; Belongs to the class of other antifungals for topical use.
J02AX01 - flucytosine ; Belongs to the class of other systemic antimycotics.
Disclaimer: This information is independently developed by CIMS based on flucytosine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in